|
Genus PLC - Basingstoke, England-based animal biotechnology and genetics - Says government approves the use of its gene edit for pigs, which provides resistance to a global disease. Porcine reproductive and respiratory syndrome causes suffering and premature death to pigs, with Genus noting a study that estimated the cost of PRRS at $1.2 billion per year in the US alone. The approval of the PRRS resistant pig programme follows years of work with multiple Canadian regulators, Genus says, and is an important step toward commercialisation in North America. Genus is seeking approval for the PRP gene edit in key North American export markets such as Mexico and Japan, as well as in China. Current stock price: 2,815.00 pence 12-month change: up 60% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
